Oxidative Stress and Redox Imbalance: Common Mechanisms in Cancer Stem Cells and Neurodegenerative Diseases DOI Creative Commons

Nikhil Raj Selvaraj,

Durga Nandan,

B J Bipin Nair

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(7), P. 511 - 511

Published: March 29, 2025

Oxidative stress (OS) is an established hallmark of cancer and neurodegenerative disorders (NDDs), which contributes to genomic instability neuronal loss. This review explores the contrasting role OS in stem cells (CSCs) NDDs. Elevated levels reactive oxygen species (ROS) contribute promote tumor initiation progression CSCs, while NDDs such as Alzheimer’s Parkinson’s disease, accelerates death impairs cellular repair mechanisms. Both scenarios involve disruption delicate balance between pro-oxidant antioxidant systems, leads chronic oxidative stress. Notably, CSCs neurons display alterations redox-sensitive signaling pathways, including Nrf2 NF-κB, influence cell survival, proliferation, differentiation. Mitochondrial dynamics further illustrate these differences: enhanced function supports adaptability whereas impairments heighten vulnerability. Understanding common mechanisms OS-induced redox imbalance may provide insights for developing interventions, addressing aging hallmarks, potentially mitigating or preventing both

Language: Английский

Molecular Mechanisms of Neuroinflammation in Aging and Alzheimer’s Disease Progression DOI Open Access
Felicia Liana Andronie-Cioară, Adriana Ioana Ardelean, Carmen Delia Nistor-Cseppento

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(3), P. 1869 - 1869

Published: Jan. 18, 2023

Aging is the most prominent risk factor for late-onset Alzheimer’s disease. associates with a chronic inflammatory state both in periphery and central nervous system, evidence thereof mechanisms leading to neuroinflammation being discussed. Nonetheless, significantly enhanced by accumulation of amyloid beta accelerates progression disease through various pathways discussed present review. Decades clinical trials targeting 2 abnormal proteins disease, tau, led many failures. As such, via different strategies could prove valuable therapeutic strategy, although much research still needed identify appropriate time window. Active focusing on identifying early biomarkers help translating these novel from bench bedside.

Language: Английский

Citations

84
Oxidative stress in Alzheimer’s disease: current knowledge of signaling pathways and therapeutics DOI

Rishika Dhapola,

Samir Kumar Beura,

Prajjwal Sharma

et al.

Molecular Biology Reports, Journal Year: 2024, Volume and Issue: 51(1)

Published: Jan. 2, 2024

Language: Английский

Citations

62
Metals in Alzheimer’s Disease DOI Creative Commons
Mirjana Babić Leko,

Lea Langer Horvat,

Ena Španić Popovački

et al.

Biomedicines, Journal Year: 2023, Volume and Issue: 11(4), P. 1161 - 1161

Published: April 12, 2023

The role of metals in the pathogenesis Alzheimer’s disease (AD) is still debated. Although previous research has linked changes essential metal homeostasis and exposure to environmental heavy AD, more needed determine relationship between AD. In this review, we included human studies that (1) compared concentrations AD patients healthy controls, (2) correlated cerebrospinal fluid (CSF) biomarkers with concentrations, (3) used Mendelian randomization (MR) assess potential contributions risk. many have examined various dementia patients, understanding dynamics these remains difficult due considerable inconsistencies among results individual studies. most consistent findings were for Zn Cu, observing a decrease levels an increase Cu patients. However, several found no such relation. Because few biomarker CSF type required. Given MR revolutionizing epidemiologic research, additional include participants from diverse ethnic backgrounds causal risk are critical.

Language: Английский

Citations

35
Levistilide A ameliorates neuroinflammation via inhibiting JAK2/STAT3 signaling for neuroprotection and cognitive improvement in scopolamine-induced Alzheimer’s disease mouse model DOI
H. Ni,

Yanfang Liao,

Yifan Zhang

et al.

International Immunopharmacology, Journal Year: 2023, Volume and Issue: 124, P. 110783 - 110783

Published: Aug. 22, 2023

Language: Английский

Citations

26
The Involvement of Neuroinflammation in the Onset and Progression of Parkinson’s Disease DOI Open Access
Anamaria Jurcău, Felicia Liana Andronie-Cioară, Carmen Delia Nistor-Cseppento

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(19), P. 14582 - 14582

Published: Sept. 26, 2023

Parkinson’s disease is a neurodegenerative exhibiting the fastest growth in incidence recent years. As with most diseases, pathophysiology incompletely elucidated, but compelling evidence implicates inflammation, both central nervous system and periphery, initiation progression of disease, although it not yet clear what triggers this inflammatory response where begins. Gut dysbiosis seems to be likely candidate for systemic inflammation. The therapies current use provide only symptomatic relief, do interfere progression. Nonetheless, animal models have shown promising results that target various vicious neuroinflammatory cascades. Translating these therapeutic strategies into clinical trials still its infancy, series issues, such as exact timing, identifying biomarkers able identify early pre-symptomatic stages, or proper indications genetic testing population at large, will need settled future guidelines.

Language: Английский

Citations

22
Regulatory roles of microRNAs in modulating mitochondrial dynamics, amyloid beta fibrillation, microglial activation, and cholinergic signaling: Implications for alzheimer's disease pathogenesis DOI
Monika Sharma, Ankur Kumar Tanwar,

Paresh Kumar Purohit

et al.

Neuroscience & Biobehavioral Reviews, Journal Year: 2024, Volume and Issue: 161, P. 105685 - 105685

Published: April 25, 2024

Language: Английский

Citations

11
Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review DOI Creative Commons
Jakub Hort, Thomas Duning, Robert Hoerr

et al.

Neuropsychiatric Disease and Treatment, Journal Year: 2023, Volume and Issue: Volume 19, P. 647 - 660

Published: March 1, 2023

Background: Many clinical trials testing Ginkgo biloba extract EGb 761 in patients with mild forms of cognitive impairment were conducted before widely accepted terms and diagnostic criteria for such conditions available. This makes it difficult to compare any results from earlier more recent trials. The objective this systematic review was provide a descriptive overview who met the neurocognitive disorder (mild NCD) according Diagnostic Statistical Manual Mental Disorders, fifth edition (DSM-5). Methods: MEDLINE, PubMed EMBASE searched randomized, placebo-controlled double-blind functioning. All involving retrospectively applied NCD included. Trials primary prevention dementia combinations medical treatments excluded. Results: Among 298 records found databases 76 further related references reviews, 9 reports on 946 pre-specified inclusion. Beneficial effects seen neuropsychological tests (8 studies), scales neuropsychiatric symptoms (3 3 geriatric rating (1 2 studies) global ratings change 1 study). Significant several domains cognition (memory, speed processing, attention executive functioning). symptoms, depression (2 anxiety study) significantly improved. No differences between treatment placebo regard rates adverse events. Discussion: included studies demonstrate benefits 761, mainly deficits NCD. drug safe well tolerated. Keywords: , disorder, NCD, impairment,

Language: Английский

Citations

19
Understanding the neuronal synapse and challenges associated with the mitochondrial dysfunction in mild cognitive impairment and Alzheimer’s disease DOI
Harkomal Verma, Prabhakar Gangwar,

Anuradha Yadav

et al.

Mitochondrion, Journal Year: 2023, Volume and Issue: 73, P. 19 - 29

Published: Sept. 12, 2023

Language: Английский

Citations

17
The Interplay of Protein Aggregation, Genetics, and Oxidative Stress in Alzheimer’s Disease: Role for Natural Antioxidants and Immunotherapeutics DOI Creative Commons
Ali Jawad, Kyonghwan Choe, Jun Sung Park

et al.

Antioxidants, Journal Year: 2024, Volume and Issue: 13(7), P. 862 - 862

Published: July 18, 2024

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that comprises amyloid-beta protein (Aβ) as main component of neuritic plaques. Its deposition considered trigger for AD pathogenesis, progression, and the clinical symptoms cognitive impairment. Some distinct pathological features include phosphorylation tau protein, oxidative stress, mitochondrial dysfunction. These consequences tend to produce reactive oxygen species (ROS), resulting in dysregulation various signaling pathways neuroinflammation neurodegeneration. The relationship between Aβ cascade stress pathogenesis like “chicken egg” story, with etiology regarding these two factors remaining question “which comes first.” However, this review, we have tried our best clarify interconnection mechanisms show precise cause-and-effect relationship. Based on above hallmarks AD, several therapeutic strategies using natural antioxidants, monoclonal antibodies, vaccines are employed anti-Aβ therapy decrease ROS, burden, chronic neuroinflammation, synaptic failure. antioxidants immunotherapeutics demonstrated significant neuroprotective effects symptomatic relief vitro vivo models, well trials AD. none them received final approval enter drug market mitigating In extensively elaborate pitfalls, assurances, important crosstalk concerning current therapy. Additionally, discuss future development more Aβ-targeted approaches optimization treatment mitigation.

Language: Английский

Citations

6
Microglia and Gut Microbiota: A Double-Edged Sword in Alzheimer's Disease DOI

Nargis Bano,

Sameera Khan,

Shakir Ahamad

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: unknown, P. 102515 - 102515

Published: Sept. 1, 2024

Language: Английский

Citations

6